tradingkey.logo
搜索

Bone Biologics Corp

BBLG
添加自选
0.850USD
-0.010-1.17%
收盘 07-31 16:00美东报价延迟15分钟
1.53M总市值
亏损市盈率 TTM

关于 Bone Biologics Corp 公司

Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Bone Biologics Corp简介

公司代码BBLG
公司名称Bone Biologics Corp
上市日期Nov 27, 2015
CEOFrelick (Jeffrey)
员工数量2
证券类型Ordinary Share
年结日Nov 27
公司地址2 Burlington Woods Dr Ste 100
城市BURLINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编01803-4551
电话17815524452
网址https://www.bonebiologics.com/
公司代码BBLG
上市日期Nov 27, 2015
CEOFrelick (Jeffrey)

Bone Biologics Corp公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
360.00
+0.28%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Mr. Jody Cain
Mr. Jody Cain
Investor Relation
Investor Relation
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
360.00
+0.28%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--

常见问题

Bone Biologics Corp的前五大股东是谁?

Bone Biologics Corp 的前五大股东如下:Mr. Jeffrey Frelick

有多少机构持有Bone Biologics Corp(BBLG)的股份?

截至2026Q1,共有17家机构持有Bone Biologics Corp的股份,合计持有的股份价值约为58.41K,占公司总股份的3.25%。与2025Q4相比,机构持股有所增加,增幅为22009.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有